Expertise in
39
conditions

Dr. Radhika Walling

Hematology
Office
7979 N Shadeland Ave Ste 200, 
Indianapolis, IN 
Offers Telehealth
Expertise in
39
conditions
Office
7979 N Shadeland Ave Ste 200, 
Indianapolis, IN 

Overview

Radhika Walling is a Hematologist practicing medicine in Indianapolis, Indiana.

Dr. Walling is highly rated in 39 conditions, according to our data. Her clinical expertise encompasses Gastroesophageal Junction Cancer, Paget Disease of the Breast, Breast Cancer, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in IN

Hospital Affiliations

Community Hospital North
Community Hospital East

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 15 Less Insurance Carriers -

Locations

Office
7979 N Shadeland Ave Ste 200, Indianapolis, IN 46250
Other Locations
Community Imaging Center-Carmel
11911 N Meridian St Ste 170, Carmel, IN 46032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pembrolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Enrollment Status: Terminated
Publish Date: July 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

4 Total Publications

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 15, 2021
Similar Doctors
Expertise in
6
conditions
Dr. Amy Shapiro
Hematology | Oncology
Expertise in
6
conditions
Dr. Amy Shapiro
Hematology | Oncology
Referral may be required

Indiana Hemophilia And Thrombosis Center Inc

8326 Naab Rd, 
Indianapolis, IN 
 (8.4 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amy Shapiro is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis.

Expertise in
25
conditions
Dr. Rafat Abonour
Hematology
Expertise in
25
conditions
Dr. Rafat Abonour
Hematology
Referral may be required

Office

11645 Illinois St, 
Carmel, IN 
 (7.5 miles away)
317-688-4800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rafat Abonour is a Hematologist practicing medicine in Carmel, Indiana. Dr. Abonour is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Transplant.

Expertise in
24
conditions
Dr. Nabil Adra
Hematology
Expertise in
24
conditions
Dr. Nabil Adra
Hematology
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (11.2 miles away)
317-944-0920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nabil Adra is a Hematologist practicing medicine in Indianapolis, Indiana. Dr. Adra is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Teratoma of the Mediastinum, Prostate Cancer, Orchiectomy, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Radhika Walling

How do I make an appointment with Dr. Radhika Walling?

You can book an appointment with Dr. Radhika Walling by calling their office at 317-621-4300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Radhika Walling a top-rated expert for Gastroesophageal Junction Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Radhika Walling is classified as an Distinguished expert for Gastroesophageal Junction Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Radhika Walling specialize in?

While Dr. Radhika Walling is a Hematology, they have specific expertise in Gastroesophageal Junction Cancer, Paget Disease of the Breast, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Radhika Walling participate in research or clinical trials?

Yes. Dr. Radhika Walling has published 4 articles and abstracts on conditions like Gastroesophageal Junction Cancer. You can view a list of Dr. Radhika Walling's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Radhika Walling accept my insurance?

Dr. Radhika Walling accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-621-4300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walling's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 27 Advanced Conditions
    View All 121 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile